Measles

Illinois Residents Can Help Play Critical Role in Protecting Local Communities by Scheduling Immunizations

Retrieved on: 
Wednesday, August 17, 2022
Risk, Influenza, Caregiver, Hepatitis, Mumps, CDC, Vaccine-preventable diseases, COVID-19, School, Rubella, Parent, Vaccine, Infection, Immunization, Vaccination, Public health, Meridian Health Plan Headquarters, Tetanus, Illinois Department of Public Health, Student, Health, Measles, Illinois Department of Human Services, Health insurance, Meridian

Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.

Key Points: 
  • Meridian Health Plan of Illinois (Meridian) is dedicated to ensuring Illinois residents have access to information and resources about routine immunizations to help protect children and communities against preventable illnesses.
  • Amid the COVID-19 pandemic, immunizations have declined, with all populations showing a downward trend from pre-pandemic routine immunization rates .
  • Routine vaccinations have proven effective in preventing serious illness within schools and communities.
  • Immunizations not only protect the individuals who are vaccinated, they also protect everyone who interacts with them.

Flu Shots Are Now Available at Walgreens Nationwide for Everyone Aged 3 and Up

Retrieved on: 
Monday, August 15, 2022
Men, Other Retail, Pharmaceutical, Specialty, Consumer, Infectious Diseases, Parenting, Retail, Children, Women, Seniors, Health, Multimedia, Ageing, Cough, Polio, Pharmacy, Pneumonia, Technology, Shingles, Department, Walgreens Boots Alliance, Influenza, Patient, Health department, COVID-19, Fever Dream, WBA, Program, Vaccine, Parent, United Nations Foundation, Immunization, Department of Health (Australia), Vaccination, Doctor of Pharmacy, Meningitis, Insurance, Nasdaq, UN, Tetanus, Measles, Minor, Health, Ministry, Pharmacist, Pharmaceutical industry, Walgreens

Walgreens is now offering flu shots for anyone aged 3 years and up at nearly 9,000 store locations nationwide to help reduce the spread of vaccine-preventable illnesses in communities.

Key Points: 
  • Walgreens is now offering flu shots for anyone aged 3 years and up at nearly 9,000 store locations nationwide to help reduce the spread of vaccine-preventable illnesses in communities.
  • To help save families a trip, Walgreens pharmacists are co-administering flu shots and other recommended vaccines during a single visit.
  • Walgreens is offering a $5 Walgreens Cash reward in August through December and a $10 Walgreens Cash reward* during the month of September to individuals who receive any vaccination at a Walgreens location.
  • To schedule an appointment for a flu shot or any vaccine at Walgreens, please visit Walgreens.com/ScheduleVaccine or download the Walgreens app.

Sunshine Biopharma Increases Support for Anti-Coronavirus Collaborative Research With the University of Arizona

Retrieved on: 
Thursday, July 28, 2022
Online, Severe acute respiratory syndrome coronavirus 2, University, College of Medicine, GLOBE, Omicron, Pharmacology, Southwestern United States, College, McGill, U.S. Securities and Exchange Commission, Drug discovery, Doctor of Philosophy, Student, Medicine, Neurodegeneration, CEO, SEC, Research, Addiction, Nursing school, Toxicology, Squamous cell carcinoma, Immune system, Safety, COVID-19, Degenerative disease, Vaccine, NASDAQ, General Hospital, Cancer, Pancreatic cancer, Company, Pharmacokinetics, Pain, Faculty, Measles, Growth, Risk, Contract, Disease, Combined small-cell lung carcinoma, Public health, Breast cancer, Pharmaceutical industry, Pharmacy

At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.

Key Points: 
  • At the University of Arizona Health Sciences, Gregory Thatcher, PhD, a professor of pharmacology and toxicology and the R. Ken and Donna Coit Endowed Chair of Drug Discovery, is leading the research effort that is progressing as planned.
  • Located on campuses in Tucson, Phoenix and Gilbert, Arizona, the University of Arizona Health Sciences is one of the top-ranked academic medical centers in the southwestern United States.
  • In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound.
  • Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.

Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Retrieved on: 
Thursday, July 21, 2022
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Vaccine, Patient, Diagnosis, Antibody, INCAT, Edema, Takeda Pharmaceutical Company, Adult, Safety, Genetics, Erythema, Product, Hematology, Clinical trial, Rubella, CIDP, Projection, Infection, IVIG, Acquisition, Investment, ADL, Primary immunodeficiency, U.S. Securities and Exchange Commission, Mumps, Union, Progressive inflammatory neuropathy, Itch, TAK, Chronic inflammatory demyelinating polyneuropathy, Advertising, Recombinant, Pain, Measles, Prevalence, SID, Fatigue, Immunoglobulin G, International Classification of Functioning, Disability and Health, Quality of life, Nausea, Peripheral nervous system, Annual report, Vomiting, R, Immunodeficiency, Maintenance, Headache, PI, Research and development, Chickenpox, SC, Medical device, Pharmaceutical industry, Gastroenterology, Fever, Takeda, Neuroscience

Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.

Key Points: 
  • Takeda ( TSE:4502/NYSE:TAK ) today announced that ADVANCE-1, a randomized, placebo-controlled, double-blind Phase 3 clinical trial evaluating HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), met its primary endpoint.
  • Of the 62 patients treated with HYQVIA, the majority of treatment-related adverse events were reported as mild or moderate.
  • ADVANCE-1 was a Phase 3, multicenter, placebo-controlled, double-blinded study to evaluate the efficacy, safety and tolerability of HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] as a maintenance therapy to prevent relapse in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
  • Some of the secondary endpoints included time to relapse, effect on activities of daily living (ADL), safety and tolerability.

Urgent response required to avert major humanitarian crisis in the Horn of Africa, Concern Worldwide US warns

Retrieved on: 
Wednesday, June 29, 2022
Water, Emergency, Livestock, Death, Horn, Measles, Media contacts database, Country, Food, UN, Milk, Risk, Famine, Concern Worldwide, Concern, Health, Malnutrition, Animal, Season, Multimedia, Income, Agriculture, Gum arabic, Cholera

NEW YORK, June 29, 2022 /PRNewswire/ -- Concern Worldwide today called for urgent international funding to assist communities in the Horn of Africa experiencing the worst drought in 40 years to avert a major humanitarian crisis in the coming months.

Key Points: 
  • NEW YORK, June 29, 2022 /PRNewswire/ -- Concern Worldwide today called for urgent international funding to assist communities in the Horn of Africa experiencing the worst drought in 40 years to avert a major humanitarian crisis in the coming months.
  • Concern Worldwide US responds to Horn of Africa drought, Ukraine humanitarian crisis & inflation causing global hunger.
  • An estimated five million children in the region are malnourished, with 1.6 million experiencing severe malnutrition, putting their lives at risk.
  • "Without an urgent response and scaling up of the humanitarian support, we risk 350,000 of these children dying," Concern's Regional Director for the Horn of Africa, Amina Abdulla, warned today.

APRU Readies for Looming Book Launch with Springer on Safety and Resilience of Higher Educational Institutions

Retrieved on: 
Tuesday, June 28, 2022
Publishing, Other Education, Continuing, Communications, University, Books, Education, Entertainment, Review, Tohoku University, Galápagos Islands, Associate professor, University, Emergency, Springer, Student, Checklist, COVID-19, Climate, Asian Institute of Technology, Iris, University of Auckland, Public health, Weather, Faculty, Types of volcanic eruptions, ID, Earthquake, Auckland University of Technology, Calamity, Lists of disasters, Senior lecturer, Pan, Safety, APRU, Temperature, Keio University, Time, Associate, Graduate school, MH, NTU, Measles, Disaster risk reduction, Center, National Taiwan University, Pharmaceutical industry, Risk management, Tutoring, Program

APRU is proud to announce that the APRU Multi-Hazards Program has facilitated the upcoming book Safety and Resilience of Higher Educational Institutions: Considerations for a Post-COVID-19 Pandemic Analysis, published by Springer.

Key Points: 
  • APRU is proud to announce that the APRU Multi-Hazards Program has facilitated the upcoming book Safety and Resilience of Higher Educational Institutions: Considerations for a Post-COVID-19 Pandemic Analysis, published by Springer.
  • Higher educational institutions (HEIs) have had to undergo significant transformations during the COVID-19 pandemic, and some countries had to cope with the pandemic and natural hazards simultaneously.
  • Izumis chapter includes a checklist for university preparedness developed under the APRU MH campus safety program.
  • Information about the book Safety and Resilience of Higher Educational Institutions:

Cepheid and BioGX Announce Collaboration to Develop Monkeypox PCR Test for the GeneXpert® System

Retrieved on: 
Monday, June 27, 2022
Government, Fever, Bacillus anthracis, Doctor of Philosophy, Chickenpox, Disease, Bacillus, World Health Organization, Mycobacterium tuberculosis, Infection, Population, Center, Anthrax, GeneXpert MTB/RIF, Simplex, Cepheid variable, World, Syphilis, Monkeypox, EVP, Skin, PCR, Flexible, Korea Disease Control and Prevention Agency, Measles, Severe acute respiratory syndrome coronavirus 2, CDC, Vaccine

SUNNYVALE, Calif. and BIRMINGHAM, Ala., June 27, 2022 /PRNewswire/ -- Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system.

Key Points: 
  • SUNNYVALE, Calif. and BIRMINGHAM, Ala., June 27, 2022 /PRNewswire/ -- Cepheid and BioGX today announced a collaboration between the two companies to deliver a PCR test for Monkeypox that will run on the GeneXpert system.
  • According to the Centers for Disease Control and Prevention (CDC), monkeypox is rare and does not spread easily between people without close contact.
  • While the threat of monkeypox to the general U.S. population remains low1, it is important for healthcare providers worldwide to have a preparedness plan.
  • The World Health Organization recommends PCR as the preferred laboratory test for monkeypox, using an appropriate skin lesion sample2.

InventHelp Inventor Develops an Improved PPE Face Mask (NJD-2423)

Retrieved on: 
Tuesday, June 21, 2022
Meningitis, Infection, Mask, NO, Tuberculosis, Multimedia, COVID-19, Hair, Ninth Street, Kool-Aid, Measles, Sale, Pharmaceutical industry

It will be easier to drop the front down to eat and drink and for people who wear hearing aids or earrings."

Key Points: 
  • It will be easier to drop the front down to eat and drink and for people who wear hearing aids or earrings."
  • This patent-pending invention provides enhanced comfort and ease of positioning or removal and does not snag hearing aids, earrings, and hair when it is removed.
  • The original design was submitted to the New Jersey sales office of InventHelp.
  • 20-NJD-2423, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Global Vaccine Adjuvants Market Report (2022 to 2035) - by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies - ResearchAndMarkets.com

Retrieved on: 
Monday, June 20, 2022
Pharmaceutical, Health, Medical Devices, Tetanus, Immunity, HIV-AIDS, Industry, Investor, Cough, Type, Administration, CpG, COVID-19, Cholera, Measles, Death, Vaccine, Public sector, 1018, Research, Antigen, USD, DNA, AS04, Diphtheria, Malaria, MF59, Cervarix, Zoster vaccine

The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Vaccine Adjuvants Market by Type of Vaccine Adjuvant, Route of Administration, Target Therapeutic Area and Key Geographies: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and future potential of the vaccine adjuvant market.
  • According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025.
  • Currently, more than 70 companies and academic / research institutes are engaged in the development of various types of vaccine adjuvants.

Comparing COVID-19 Disinfection Efficacy of UVC LED Devices to Low-Pressure Mercury (LPUV) UVC Lamps

Retrieved on: 
Monday, June 20, 2022
COVID-19, Safety, Scalability, Tuberculosis, UVC, Measles, School, IES, Disinfectant, UVGI, SARS, Hospital, Biophysical environment, Infection, Virus, Severe acute respiratory syndrome coronavirus 2, Lung, Health, ASHRAE, Atmosphere, HVAC, CDC, Mercury, Sewage, Heating, ventilation, and air conditioning, Ozone, Bacteria

NORTHVALE, N.J., June 20, 2022 /PRNewswire/ -- Olympia's patented cutting-edge Air Disinfection fixtures ensure work environments are kept germ-free and businesses resume daily activities. The workspaces where these fixtures can be used include hospitals, hotels, offices, clinics, schools, and other buildings such as churches. Reducing the spread of dangerous viruses and other pathogens improves air quality, safety, and health.

Key Points: 
  • The workspaces where these fixtures can be used include hospitals, hotels, offices, clinics, schools, and other buildings such as churches.
  • Olympia's UVC LED Air Disinfection devices effectively reduce COVID-19 contamination, enabling air and surface disinfection of up to 99.9% microbial reduction.
  • Olympia's UVC LED Air Disinfection Devices are built to produce the optimal UVC wavelength for disinfection to foster a clean and healthy indoor space.
  • Unlike mercury UV lamp devices, Olympia uses 265nm UVC LEDs for its UV energy source.